ReviewHistology and histopathology2026
Molecular and clinicopathological characteristics of
Hui Tang, Ting Sun, Jie Zhou, Huifang Zhang, Mingfeng Li, Zhiyin Xie, Yan Zhao
Abstract readReviewCase Reports
In one paragraphReview in Histology and histopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors.
Hui Tang *Department of Pathology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Ting Sun *Department of Pathology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Jie Zhou *Department of Pathology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Huifang ZhangDepartment of Pathology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Mingfeng LiDepartment of Pathology, Northern Jiangsu People's Hospital, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, Jiangsu, China.
Zhiyin XieDepartment of Thyroid Breast Surgery, Huai'an Hospital Affiliated to Yangzhou University, The Fifth People's Hospital of Huai'an, Huai'an, Jiangsu, China.
Yan ZhaoMedical Research Center, Northern Jiangsu People's Hospital, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, Jiangsu, China. zhaoyan1982@foxmail.com.
Funding
Innovative Talent Support Program of Zhejiang Medical and Health Research Project 2020RC056Innovative Talent Support Program of Zhejiang Medical and Health Research Project (Zhejiang Province) 2020RC056Lv Yang Jin Feng Talent Program of Yangzhou LYJF00039Natural Science Foundation of Zhejiang Province LY22H090021Yangzhou Science and Technology Planning YZ2023100
6 · The paper itselfAbstract
Neurotrophic tyrosine receptor kinase (
Indexed as
Biomarkers, TumorOncogene Proteins, FusionReceptor, trkAReceptor, trkCThyroid Cancer, PapillaryThyroid NeoplasmsETS Translocation Variant 6 ProteinFemaleGene FusionHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMiddle AgedProto-Oncogene Proteins c-etsRetrospective StudiesYoung AdultBiomarkers, TumorETS Translocation Variant 6 ProteinETV6-NTRK3 fusion protein, humanNTRK1 protein, humanNTRK3 protein, humanOncogene Proteins, FusionProto-Oncogene Proteins c-etsReceptor, trkAReceptor, trkC
What OpenQuestion holds
Textmetadata
Read underepoch 390